GlassScriptPhysician profile
Norma V Davis
NPI 1538570619
$25,287.44
in general payments reported to CMS, 2019-2025
64 companies · $5,228 in 2025
The $5,228 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,049 · 2022: $4,764 · 2023: $5,304 · 2024: $4,943 · 2025: $5,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,374.33 |
| Education | $100.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,230.21 | 2021-2025 | |
| Amgen INC. | $1,510.57 | 2021-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $1,416.49 | 2021-2025 | Tezspire, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,352.96 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $1,218.56 | 2021-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,192.39 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,023.74 | 2021-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Teva Pharmaceuticals USA, INC. | $975.85 | 2021-2022 | |
| Genzyme Corporation | $954.15 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $923.37 | 2021-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $737.91 | 2021-2025 | Rexulti, Vyepti |
| Sanofi-Aventis U.S. LLC | $694.66 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $630.97 | 2021-2024 | |
| Abbott Laboratories | $563.73 | 2021-2025 | Freestyle Libre 3, Jeti Peripheral Catheter |
| Lilly USA, LLC | $510.86 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $492.59 | 2021-2023 | |
| Novo Nordisk INC | $440.92 | 2022-2025 | Rybelsus, Wegovy, Ozempic |
| Esperion Therapeutics, INC. | $423.54 | 2021-2025 | Nexletol |
| Ironwood Pharmaceuticals, INC | $403.65 | 2021-2024 | Linzess |
| Cmp Pharma, INC. | $378.43 | 2021-2023 | Tadliq, Norliqva, Carospir |
| Amarin Pharma, INC. | $373.16 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $347.42 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $334.58 | 2022-2025 | Verquvo, Dificid, Belsomra |
| Regeneron Healthcare Solutions, INC. | $296.98 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $289.40 | 2022-2025 | Ibsrela |
| Exact Sciences Corporation | $241.25 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $239.92 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $239.90 | 2023-2025 | Gemtesa |
| Mylan Specialty L.P. | $237.89 | 2023-2024 | Yupelri |
| Shield Therapeutics INC | $178.22 | 2023-2025 | Accrufer |
| Biohaven Pharmaceuticals, INC. | $146.68 | 2021 | |
| Antares Pharma, INC. | $141.51 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Cequr Corporation | $138.61 | 2022-2025 | Cequr Simplicity |
| Viatris Specialty LLC | $130.56 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $126.04 | 2022-2023 | Trintellix |
| Pfizer INC. | $123.81 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $115.84 | 2022 | |
| Endo Pharmaceuticals INC. | $109.33 | 2021 | |
| Alkermes, INC. | $106.45 | 2022-2025 | Aristada, Lybalvi |
| Kowa Pharmaceuticals America, INC. | $105.57 | 2021-2025 | Zoryve, Seglentis |
| Janssen Pharmaceuticals, INC | $103.15 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $100.46 | 2024-2025 | Fanapt, Hetlioz |
| Actelion Pharmaceuticals US, INC. | $85.65 | 2022 | |
| Idorsia Pharmaceuticals US INC | $81.33 | 2022-2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $80.70 | 2021 | |
| Horizon Therapeutics Plc | $78.66 | 2021-2022 | |
| Harmony Biosciences LLC | $78.51 | 2025 | |
| Allergan, INC. | $70.98 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.73 | 2022-2023 | |
| Paratek Pharmaceuticals, INC. | $64.29 | 2021-2023 | Nuzyra |
| Lexicon Pharmaceuticals, INC. | $51.71 | 2024 | |
| Axsome Therapeutics, INC. | $40.82 | 2024-2025 | Auvelity |
| Halozyme INC | $38.62 | 2023 | |
| Myriad Women'S Health, INC. | $35.16 | 2023 | Myrisk |
| Azurity Pharmaceuticals, INC. | $33.22 | 2023 | Horizant |
| Daiichi Sankyo INC. | $28.72 | 2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $23.36 | 2024 | Voquezna |
| Almirall LLC | $23.20 | 2021 | |
| Corcept Therapeutics | $21.44 | 2025 | Korlym |
| Biogen, INC. | $17.95 | 2021 | |
| Almatica Pharma LLC | $16.22 | 2021 | |
| Phadia US INC. | $15.59 | 2023 | Immunocap |
| Acerus Pharmaceuticals Corporation | $14.96 | 2022 | |
| Bausch Health US, LLC | $14.34 | 2024 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norma Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.